目的 探讨术前白细胞计数对超“米兰标准”肝细胞癌病人肝切除预后的预测价值。方法 回顾性分析 2007年6月至2013年12月在天津医科大学肿瘤医院行肝切除的237例超“米兰标准”肝细胞癌病人的临床资料。利用ROC曲线确定白细胞计数分界值,对病人分组。应用Kaplan-Meier法制作生存曲线,Log-Rank法进行分析。应用COX比例风险模型研究影响预后的危险因素。结果 白细胞计数6.0×109/L为分界值。白细胞较低组和白细胞较高组中位生存时间分别为53.4个月和27.6个月（P=0.002）。白细胞较低组和白细胞较高组中位无复发生存时间分别为20.7个月和12.2个月（P=0.029）。匹配分析后两组间生存时间及无复发生存时间仍有统计学差异。结论 术前白细胞计数可预测超“米兰标准”肝细胞癌病人肝切除的预后。
侯振宇, 孔银龙, 张勇强, 朱科云, 杨雪娇, 陈平, 李慧锴, 崔云龙, 宋天强, 李强, 张倜
. 术前白细胞计数预测肝切除治疗超“米兰标准”肝细胞癌病人的预后[J]. 外科理论与实践, 2018
, 23(04)
: 358
-362
.
DOI: 10.16139/j.1007-9610.2018.04.017
Objective To study the prognostic value of preoperative white blood cell (WBC) count in patients with hepatocellular carcinoma(HCC) beyond Milan criteria after hepatic resection. Methods Clinical data of 237 patients with HCC beyond Milan criteria from Tianjin Medical University Cancer Hospital who underwent hepatectomy from June 2007 to December 2013 were retrospectively studied. The cut-off value of WBC count was determined by receiver operating characteristic curve, which was used to divide the patients in two groups. Survival curves were formed with Kaplan-Meier method and were analyzed using Log-Rank test. Cox proportional hazards model was developed to identify the risk factors of survival. Results WBC count 6.0 ×109/L was the cut-off point between two groups. The median survival time of lower WBC count group and higher WBC count group were 53.4 and 27.6 months, respectively (P=0.002). The median recurrence-free survival of lower WBC count group and higher WBC count group were 20.7 and 12.2 months, respectively(P=0.029). The statistical differences in both survival time and recurrence-free survival remained between two groups after match analysis. Conclusions Preoperative WBC count might predict the prognosis of HCC patients beyond Milan criteria after hepatic resection.
[1] Bruix J, Gores GJ, Mazzaferro V.Hepatocellular carcinoma: clinical frontiers and perspectives[J]. Gut,2014,63(5):844-855.
[2] Forner A, Llovet JM, Bruix J.Hepatocellular carcinoma[J]. Lancet,2012,379(9822):1245-1255.
[3] Bruix J, Sherman M, American Association for the Study of Liver Disease. Management of hepatocellular carcinoma: an update[J]. Hepatology,2011,53(3):1020-1022.
[4] European Association for the Study of the Liver, European Organisation for Research, Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma[J]. J Hepatol,2012,56(4):908-943.
[5] Zhong JH, Ke Y, Gong WF, et al.Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma[J]. Ann Surg,2014,260(2):329-340.
[6] Sakamoto K, Nagano H.Surgical treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus[J]. Hepatol Res,2017,47(10):957-962.
[7] Torzilli G, Belghiti J, Kokudo N, et al.A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations? an observational study of the HCC East-West study group[J]. Ann Surg,2013,257(5):929-937.
[8] Yang T, Lin C, Zhai J, et al.Surgical resection for advanced hepatocellular carcinoma according to Barcelona Clinic Liver Cancer (BCLC) staging[J]. J Cancer Res Clin Oncol,2012,138(7):1121-1129.
[9] Grimm RH Jr, Neaton JD, Ludwig W.Prognostic importance of the white blood cell count for coronary, cancer, and all-cause mortality[J]. JAMA,1985,254(14):1932-1937.
[10] Shankar A, Wang JJ, Rochtchina E, et al.Association between circulating white blood cell count and cancer mortality: a population-based cohort study[J]. Arch Intern Med,2006,166(2):188-194.
[11] Erlinger TP, Muntner P, Helzlsouer KJ.WBC count and the risk of cancer mortality in a national sample of U.S. adults: results from the Second National Health and Nutrition Examination Survey mortality study[J]. Cancer Epidemiol Biomarkers Prev,2004,13(6):1052-1056.
[12] Jee SH, Park JY, Kim HS, et al.White blood cell count and risk for all-cause, cardiovascular, and cancer mortality in a cohort of Koreans[J]. Am J Epidemiol,2005,162(11):1062-1069.
[13] Huang W, Wang F, Li Y, et al.Leukemoid reaction in sarcomatoid renal cell carcinoma: a two-case report[J]. World J Surg Oncol,2014,12:100.
[14] Riesenberg H, Muller F, Gorner M.Leukemoid reaction in a patient with adenocarcinoma of the lung: a case report[J]. J Med Case Rep,2012,6:211.
[15] Coffelt SB, De Visser KE.Cancer: Inflammation lights the way to metastasis[J]. Nature,2014,507(7490):48-49.
[16] Colotta F, Allavena P, Sica A, et al.Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability[J]. Carcinogenesis,2009,30(7):1073-1081.
[17] Solinas G, Marchesi F, Garlanda C, et al.Inflammation-mediated promotion of invasion and metastasis[J]. Cancer Metastasis Rev,2010,29(2):243-248.
